Kyle Gano
Vermögen: 24 Mio $ am 31.08.2026
Vermögen: 24 Mio $ am 31.08.2026
Kyle W.
Gano is currently President, Chief Executive Officer & Director at Neurocrine Biosciences, Inc. since 2024.
Dr. Gano is also a Director at Pharmaceutical Research & Manufacturers of America since 2024.
Education history includes an undergraduate degree from the University of Washington in 1996, an MBA and a doctorate from the University of California, Los Angeles, and an undergraduate degree from the University of Oregon.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 11.09.2026 | 154.728 ( 0,15 % ) | 24 Mio $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| NEUROCRINE BIOSCIENCES, INC. | Vorstandsvorsitzender | 11.10.2024 |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Provides pharmaceutical research and biotechnology services | Direktor/Vorstandsmitglied | 01.10.2024 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes treatments for neurological, neuroendocrine and neuropsychiatric disorders | Health Technology |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oregon
University of Oregon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Provides pharmaceutical research and biotechnology services | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen